Insulet (NASDAQ:PODD) Stock Sale Reported by Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Rep. Gilbert Ray Cisneros Jr. sold between $1,001 and $15,000 of Insulet stock on September 18, according to a filing disclosed October 12.
• Insulet reported quarterly EPS of $1.66, exceeding the $1.47 consensus estimate, while revenue rose 23.5% year over year to $801.7 million.
• Analysts have a consensus “Hold” rating on Insulet, with an average price target of $186.68; the stock opened at $138.13 and has traded between $126.40 and $354.88 over the past year.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Insulet Corporation (NASDAQ:PODD). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Insulet stock on September 18th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Benchmark Electronics NYSE: BHE on 10/1/2026.
• Sold $1,001 - $15,000 in shares of Oxford Industries NYSE: OXM on 9/29/2026.
• Sold $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 9/29/2026.
• Sold $15,001 - $50,000 in shares of ITT NYSE: ITT on 9/29/2026.
• Sold $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Tandem Diabetes Care NASDAQ: TNDM on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Cytokinetics NASDAQ: CYTK on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Ultragenyx Pharmaceutical NASDAQ: RARE on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of YETI NYSE: YETI on 9/29/2026.
• Sold $1,001 - $15,000 in shares of AtriCure NASDAQ: ATRC on 9/29/2026.

Insulet Price Performance

PODD opened at $138.13 on Wednesday. The stock's 50 day simple moving average is $140.56 and its 200 day simple moving average is $158.02. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. Insulet Corporation has a 1 year low of $126.40 and a 1 year high of $354.88. The firm has a market cap of $9.58 billion, a price-to-earnings ratio of 25.82, a PEG ratio of 1.10 and a beta of 1.11.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping analysts' consensus estimates of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The business had revenue of $801.70 million for the quarter, compared to analysts' expectations of $787.39 million. During the same period in the previous year, the firm earned $1.17 EPS. The business's quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, analysts predict that Insulet Corporation will post 6.51 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on PODD shares. Royal Bank Of Canada lowered their price target on Insulet from $245.00 to $160.00 and set an "outperform" rating for the company in a research report on Thursday, August 6th. Citigroup lifted their price objective on Insulet from $165.00 to $172.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 8th. Oppenheimer cut Insulet from an "outperform" rating to a "market perform" rating in a research note on Wednesday, August 5th. BTIG Research lowered Insulet from a "buy" rating to a "neutral" rating in a research note on Thursday, August 6th. Finally, Evercore set a $180.00 price target on shares of Insulet in a report on Monday, July 6th. Thirteen analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $186.68.

Hedge Funds Weigh In On Insulet

Several institutional investors and hedge funds have recently added to or reduced their stakes in PODD. Elevation Wealth Partners LLC lifted its position in Insulet by 115.6% in the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier's stock worth $25,000 after buying an additional 104 shares during the last quarter. MV Capital Management Inc. bought a new position in Insulet during the fourth quarter valued at $29,000. Continuum Advisory LLC bought a new position in Insulet during the second quarter valued at $46,000. Sound Income Strategies LLC raised its stake in shares of Insulet by 4,620.0% in the first quarter. Sound Income Strategies LLC now owns 236 shares of the medical instruments supplier's stock valued at $49,000 after acquiring an additional 231 shares during the period. Finally, State of Wyoming raised its stake in shares of Insulet by 34.6% in the first quarter. State of Wyoming now owns 284 shares of the medical instruments supplier's stock valued at $60,000 after acquiring an additional 73 shares during the period.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps.

Insulet's product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.